Miguel Bronchud: Good news for the commonest clinical kidney cancer
Miguel Bronchud, Co-Founder & Advisory Board at Regenerative Medicine Solutions, shared an article on LinkedIn:
“Good news for the commonest clinical kidney cancer:
Most kidney cancer (RCC) diagnoses (more than 3 out of five ) in the UK are incidental and found as a result of unrelated medical interventions, or imaging diagnostic procedures- according to a recent report by Kidney Cancer UK.
Partial nephrectomy (PN) has become the reference standard for most T1 and T2 early cancer masses. In cT2 RCC, PN exhibits oncological equivalence and improved functional outcomes compared to radical nephrectomy (RN). Additionally, emerging data suggest that PN may be used to treat cT3a RCC.
The robot-assisted platform is increasingly used to treat locally advanced RCC. Studies suggest safety and feasibility of robotic RN and robotic inferior vena cava tumor thrombectomy. Additionally, single-port robot-assisted laparoscopic approaches are comparable to multiport approaches in select patients.
Long-term data show that cryoablation, radiofrequency ablation, and microwave ablation are equipotent in management of small renal masses. Emerging data suggest that microwave may effectively treat cT1b masses.
Indeed, a recent meta analysis (Canadian/USA) published in The Lancet Oncology suggests comparative efficacy (95% circa) and safety of non surgical ablative therapies in the management of primary localised renal cell carcinoma (RCC) (a systematic review and meta-analysis – The Lancet Oncology). The proportion of patients who reported grade 3–4 adverse events was 3% (121 of 3726) after cryoablation, 2% (39 of 2503) after radiofrequency ablation, 1% (22 of 2069) after microwave ablation, and 2% (11 of 612) after SBRT. Risk of bias was moderate in most studies (70 [53%] of 133) and no publication bias was observed.
A recent study by Toni Choueiri and colleagues showing that combination immunotherapy with a cancer vaccine helped prevent kidney cancer recurrence has also been published.
Braun, D.A., Moranzoni, G., Chea, V. et al. A neoantigen vaccine generates antitumour immunity in renal cell carcinoma. Nature (2025).”
Recent Advances in the Management of Localized and Locally Advanced Renal Cell Carcinoma: A Narrative Review.
Authors: Sohail Dhanji, et al.
A neoantigen vaccine generates antitumour immunity in renal cell carcinoma.
Authors: David A. Braun, et al.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023